EFFECT OF HYDROXYUREA ON THE FREQUENCY OF PAINFUL CRISES IN SICKLE-CELL-ANEMIA
EFFECT OF HYDROXYUREA ON THE FREQUENCY OF PAINFUL CRISES IN SICKLE-CELL-ANEMIA
复制标题
DOI：
10.1056/nejm199505183322001
复制
发表时间：
1995-05-18
影响因子：
158.5
通讯作者：
WACLAWIW, M
中科院分区：
文献类型：
--
作者：
CHARACHE, S;TERRIN, ML;WACLAWIW, M
背景在之前的一项关于羟基脲治疗的开放标签研究中，大多数镰状细胞贫血患者的胎儿血红蛋白合成增加，仅伴有轻度骨髓毒性。通过抑制镰状化，胎儿血红蛋白水平的增加可能会降低疼痛的频率。在一项双盲随机临床试验中，我们测试了羟基脲在降低每年有三次或三次以上疼痛危象史的成人疼痛危象频率方面的疗效。平均随访21个月后，试验停止。在21家诊所的148名男性和151名女性中，152名接受羟基脲治疗的患者的年危象发生率低于147名接受安慰剂治疗的患者（中位数，每年2.5对4.5次危象，P
Background. In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises.Methods. In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year. The trial was stopped after a mean follow-up of 21 months.Results. Among 148 men and 151 women studied at 21 clinics, the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P